Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

751P - Infantile versus adult-type fibrosarcoma and the risk of multiple primary malignancies

Date

07 Dec 2024

Session

Poster Display session

Presenters

Huda Sherif

Citation

Annals of Oncology (2024) 35 (suppl_4): S1679-S1697. 10.1016/annonc/annonc1699

Authors

H.A. Sherif1, H. Hamouda1, N. Sobhy2, E. Hamouda2, A. Ellaithy3

Author affiliations

  • 1 Faculty Of Medicine, Menoufeya University Faculty of Medicine, 11361 - Cairo/EG
  • 2 Faculty Of Medicine, Menoufia University, 32511 - Shebeen El-Kom/EG
  • 3 Faculty Of Medicine, Suez Canal University Hospital, 41522 - Ismailia/EG

Resources

This content is available to ESMO members and event participants.

Abstract 751P

Background

Fibrosarcoma is a rare malignant neoplasm representing 10% of musculoskeletal sarcomas and less than 5% of all primary bone tumors. It is classified as infantile fibrosarcoma (IFS) and adult-type fibrosarcoma. Second primary malignancies (SPMs) are a potential serious risk that can occur in fibrosarcoma survivors. Since there are no available studies analyzing this issue, we aimed to assess the risk of SPMs following primary fibrosarcoma diagnosis for better understanding of the nature of this rare neoplasm.

Methods

We selected patients diagnosed with fibrosarcoma from 2000 to 2021 using SEER*stat software. We used an MP-SIR session to calculate the standardized incidence ratio (SIR) as Observed/Expected (O/E) and the excess risk (ER) per 10,000. We subgrouped them histologically: IFS, fibromyxosarcoma, periosteal fibrosarcoma, facial fibrosarcoma, dermatofibrosarcoma, central odontogenic fibrosarcoma and ameloblastic fibrosarcoma.

Results

Out of 12783 fibrosarcoma patients, 1048 (8.2%) developed SPMs. The majority were Caucasians (71.1%) and 50.2% were females. A significant risk of SPMs was observed in all sites (O/E=1.46, P<0.05, ER=35.21). However, IFS had no risk to develop SPMs (Observed=1, O/E=1.85, P>0.05, ER= 4.26). Dermatofibrosarcoma had a high SPMs risk (O/E=1.52, P<0.05, 95% CI: 1.41-1.64) and fibromyxosarcoma had an O/E of 1.40 (P<0.05, 95% CI: 1.24-1.58). Fibromyxosarcoma had an alarming risk for SPMs if originated in the heart and soft tissue (O/E=32.38, P<0.05, 95% CI: 23.2-43.9). The risk of SPMs was notably higher in the young age (O/E=5.21, P<0.05). Respiratory system SPMs had an increased risk among fibrosarcoma survivors (O/E=1.84, P< 0.05, 95% CI: 1.03-3.04, ER=10.53). Fibrosarcoma had statistically insignificant risk to develop bone SPMs (Observed=1, O/E=1.00, P>0.05).

Conclusions

The results of this study reveal high risk of multisystem SPMs following primary fibrosarcoma especially for caucasians and females. However, IFS had insignificant risk of SPMs compared to adult-type fibrosarcomas. The most frequent sites for SPMs were the heart and soft tissue across all races, genders, ages, and histological types. Thus, more attention is needed for SPMs screening after the diagnosis of adult-type fibrosarcomas.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.